Sales of obesity drugs have been on the decline
By An, Kyung-Jin | translator Choi HeeYoung
21.05.25 10:52:20
가나다라
0
Sales of obesity treatment drugs in South Korea in first quarter decreased by ₩32 billion and 2% compared to last year
Sales of the No. 1 Saxenda, fell 25% on-year to ₩6.7 billion
Qsymia, the second-largest item in sales, has a turnover of ₩5.9 billion
The rise in the obesity treatment market, which had high sales, has slowed. The effects of the new products of Saxenda and Qsymia has decreased.
According to IQVIA, a pharmaceutical research institute, the domestic obesity treatment drug market was ₩32 billion in the first quarter, down 2.4% from ₩32.8 billion a year earlier.
Although its sales in 3rd quarter of last year were at an all-time high of ₩38.5 billion, it fell for the second consecutive quarter. This is similar to the amount of sales immediately after Belviq (Lorcaserin) was removed due to safety issues in the fourth quarter of 2019.
The reason why the obesity drug market is sluggish is mainly
An, Kyung-Jin(kjan@dailypharm.com)
If you want to see the full article, please JOIN US (click)